ATRA · Atara Biotherapeutics, Inc. · Congressional Trades
$7.93
-0.30 (-3.65%)
At close · Nov 12
Return incl. dividend (before tax)
Q3 2023 earnings call transcript
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$80.79M
Shares
10.19M
Volume · Nov 12
16.7K
Avg daily vol (3M)
38.48K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Transactions in this listed security by members of the U.S. Congress, disclosed under the STOCK Act. Lawmakers must report trades within 45 days, so the filing date can lag the trade itself.
No Congressional Trades
No congressional trading data is available for this listed security yet.
Key facts
CIK
1604464
CUSIP
046513206
13F (30d)
31 filings
18 filers
Visit website
Investor relations